Reo Tanoshima

Influence of <i>CYP3A5</i> and <i>ABCB1</i> gene polymorphisms on calcineurin inhibitor‐related neurotoxicity after hematopoietic stem cell transplantation

Masakatsu Yanagimachi, Takuya Naruto, Reo Tanoshima et al. · Clinical Transplantation · 2009 · 69 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

High <i><scp>PRDM</scp>16</i> expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to <i><scp>FLT</scp>3</i>‐<scp>ITD</scp>,<i><scp>KMT</scp>2A</i>‐<scp>PTD</scp>, and <i><scp>NUP</scp>98‐<scp>NSD</scp>1</i>: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group <scp>AML</scp>‐05 trial

Norio Shiba, Kentaro Ohki, Tohru Kobayashi et al. · British Journal of Haematology · 2015 · 51 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura

Shoko Goto, Hiroaki Goto, Reo Tanoshima et al. · International Journal of Hematology · 2009 · 40 citations · Full text

Life Sciences, Immunology, Pediatrics +16

Influence of <i>ADORA2A</i> gene polymorphism on leukoencephalopathy risk in MTX‐treated pediatric patients affected by hematological malignancies

Shin‐ichi Tsujimoto, Masakatsu Yanagimachi, Reo Tanoshima et al. · Pediatric Blood & Cancer · 2016 · 33 citations

Medicine, Hematology, Pharmacology +14

Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy

Masakatsu Yanagimachi, Hiroaki Goto, Tetsuji Kaneko et al. · International Journal of Hematology · 2013 · 28 citations

Pharmacy, Nephrology, Pharmacokinetics +16